BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wahid R, Simon JK, Picking WL, Kotloff KL, Levine MM, Sztein MB. Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. Clin Immunol 2013;148:35-43. [PMID: 23649043 DOI: 10.1016/j.clim.2013.03.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wahid R, Kotloff KL, Levine MM, Sztein MB. Cell mediated immune responses elicited in volunteers following immunization with candidate live oral Salmonella enterica serovar Paratyphi A attenuated vaccine strain CVD 1902. Clin Immunol 2019;201:61-9. [PMID: 30849494 DOI: 10.1016/j.clim.2019.03.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
2 Toapanta FR, Simon JK, Barry EM, Pasetti MF, Levine MM, Kotloff KL, Sztein MB. Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans. Front Immunol 2014;5:374. [PMID: 25191323 DOI: 10.3389/fimmu.2014.00374] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
3 Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AKM. Shigellosis. Lancet 2018;391:801-12. [PMID: 29254859 DOI: 10.1016/S0140-6736(17)33296-8] [Cited by in Crossref: 167] [Cited by in F6Publishing: 96] [Article Influence: 33.4] [Reference Citation Analysis]
4 Shimanovich AA, Buskirk AD, Heine SJ, Blackwelder WC, Wahid R, Kotloff KL, Pasetti MF. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study. Clin Vaccine Immunol 2017;24:e00412-16. [PMID: 27927680 DOI: 10.1128/CVI.00412-16] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
5 Amadou Amani S, Lang ML. Bacteria That Cause Enteric Diseases Stimulate Distinct Humoral Immune Responses. Front Immunol 2020;11:565648. [PMID: 33042146 DOI: 10.3389/fimmu.2020.565648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Toapanta FR, Bernal PJ, Kotloff KL, Levine MM, Sztein MB. T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans. J Transl Med 2018;16:61. [PMID: 29534721 DOI: 10.1186/s12967-018-1439-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Brunner K, Samassa F, Sansonetti PJ, Phalipon A. Shigella-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses. Hum Vaccin Immunother 2019;15:1317-25. [PMID: 30964713 DOI: 10.1080/21645515.2019.1594132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
8 McArthur MA, Maciel M Jr, Pasetti MF. Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward. Vaccine 2017;35:6803-6. [PMID: 28558984 DOI: 10.1016/j.vaccine.2017.05.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
9 Venkatesan MM, Ballou C, Barnoy S, McNeal M, El-Khorazaty J, Frenck R, Baqar S. Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding. PLoS One 2021;16:e0259361. [PMID: 34793505 DOI: 10.1371/journal.pone.0259361] [Reference Citation Analysis]
10 Clarkson KA, Porter CK, Talaat KR, Frenck RW Jr, Alaimo C, Martin P, Bourgeois AL, Kaminski RW. Shigella-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei. mSphere 2021;6:e0012221. [PMID: 34259559 DOI: 10.1128/mSphere.00122-21] [Reference Citation Analysis]
11 Mani S, Toapanta FR, McArthur MA, Qadri F, Svennerholm AM, Devriendt B, Phalipon A, Cohen D, Sztein MB. Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development. Vaccine 2019;37:4787-93. [PMID: 31230883 DOI: 10.1016/j.vaccine.2019.03.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Holmgren J, Parashar UD, Plotkin S, Louis J, Ng S, Desauziers E, Picot V, Saadatian-elahi M. Correlates of protection for enteric vaccines. Vaccine 2017;35:3355-63. [DOI: 10.1016/j.vaccine.2017.05.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
13 Heine SJ, Diaz-McNair J, Andar AU, Drachenberg CB, van de Verg L, Walker R, Picking WL, Pasetti MF. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes. J Immunol 2014;192:1630-40. [PMID: 24453241 DOI: 10.4049/jimmunol.1302743] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
14 Cohen D, Meron-Sudai S, Bialik A, Asato V, Goren S, Ariel-Cohen O, Reizis A, Hochberg A, Ashkenazi S. Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis. Hum Vaccin Immunother 2019;15:1401-8. [PMID: 31070988 DOI: 10.1080/21645515.2019.1606971] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
15 Ashkenazi S, Cohen D. An update on vaccines against Shigella. Ther Adv Vaccines 2013;1:113-23. [PMID: 24757519 DOI: 10.1177/2051013613500428] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
16 Ndungo E, Pasetti MF. Functional antibodies as immunological endpoints to evaluate protective immunity against Shigella. Hum Vaccin Immunother 2020;16:197-205. [PMID: 31287754 DOI: 10.1080/21645515.2019.1640427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sow SO, Tapia MD, Chen WH, Haidara FC, Kotloff KL, Pasetti MF, Blackwelder WC, Traoré A, Tamboura B, Doumbia M, Diallo F, Coulibaly F, Onwuchekwa U, Kodio M, Tennant SM, Reymann M, Lam DF, Gurwith M, Lock M, Yonker T, Smith J, Simon JK, Levine MM. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator. Clin Vaccine Immunol 2017;24:e00265-17. [PMID: 29021299 DOI: 10.1128/CVI.00265-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Sciré AS, Maugard A, Marchetti E, Zancan S, Huo Z, Rondini S, Marhaba R, Finco O, Martin LB, Auerbach J, Cohen D, Saul A, Gerke C, Podda A. Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. EBioMedicine 2017;22:164-72. [PMID: 28735965 DOI: 10.1016/j.ebiom.2017.07.013] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
19 Barton AJ, Hill J, Pollard AJ, Blohmke CJ. Transcriptomics in Human Challenge Models. Front Immunol 2017;8:1839. [PMID: 29326715 DOI: 10.3389/fimmu.2017.01839] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
20 DeLaine BC, Wu T, Grassel CL, Shimanovich A, Pasetti MF, Levine MM, Barry EM. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine. Pathog Dis 2016;74:ftw034. [PMID: 27106253 DOI: 10.1093/femspd/ftw034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chen WH, Kotloff KL. Shigella Vaccine Development: Finding the Path of Least Resistance. Clin Vaccine Immunol 2016;23:904-7. [PMID: 27707764 DOI: 10.1128/CVI.00444-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
22 Yagnik B, Sharma D, Padh H, Desai P. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model. Vaccine 2019;37:3097-105. [PMID: 31047673 DOI: 10.1016/j.vaccine.2019.04.053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Davis CL, Wahid R, Toapanta FR, Simon JK, Sztein MB. A clinically parameterized mathematical model of Shigella immunity to inform vaccine design. PLoS One 2018;13:e0189571. [PMID: 29304144 DOI: 10.1371/journal.pone.0189571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Cheung M, Shen DK, Makino F, Kato T, Roehrich AD, Martinez-Argudo I, Walker ML, Murillo I, Liu X, Pain M, Brown J, Frazer G, Mantell J, Mina P, Todd T, Sessions RB, Namba K, Blocker AJ. Three-dimensional electron microscopy reconstruction and cysteine-mediated crosslinking provide a model of the type III secretion system needle tip complex. Mol Microbiol 2015;95:31-50. [PMID: 25353930 DOI: 10.1111/mmi.12843] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
25 Micoli F, Rossi O, Conti V, Launay O, Sciré AS, Aruta MG, Nakakana UN, Marchetti E, Rappuoli R, Saul A, Martin LB, Necchi F, Podda A. Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension. Front Immunol 2021;12:671325. [PMID: 34017343 DOI: 10.3389/fimmu.2021.671325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Cohen D, Atsmon J, Artaud C, Meron-sudai S, Gougeon M, Bialik A, Goren S, Asato V, Ariel-cohen O, Reizis A, Dorman A, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard LA, Phalipon A. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study. The Lancet Infectious Diseases 2021;21:546-58. [DOI: 10.1016/s1473-3099(20)30488-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]